Page last updated: 2024-08-23

dermatan sulfate and Morbid Obesity

dermatan sulfate has been researched along with Morbid Obesity in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Castelino, RL; Kairaitis, L; Maddula, M; Sud, K; Tarafdar, S	1

Other Studies

1 other study(ies) available for dermatan sulfate and Morbid Obesity

Article	Year
Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing. Thrombosis research, 2019, Volume: 180 Topics: Anticoagulants; Chondroitin Sulfates; Dermatan Sulfate; Dose-Response Relationship, Drug; Female; Heparin; Heparitin Sulfate; Humans; Obesity, Morbid; Renal Dialysis; Thrombocytopenia; Thrombosis	2019

Article

Year

Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.

Thrombosis research, 2019, Volume: 180

Topics: Anticoagulants; Chondroitin Sulfates; Dermatan Sulfate; Dose-Response Relationship, Drug; Female; Heparin; Heparitin Sulfate; Humans; Obesity, Morbid; Renal Dialysis; Thrombocytopenia; Thrombosis

2019